ChemicalBook >> CAS DataBase List >>2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole
2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole
![2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole Structure](CAS/20200401/GIF/1401728-56-0.gif)
- CAS No.
- 1401728-56-0
- Chemical Name:
- 2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole
- Synonyms
- GPR4 antagonist 3;NE 52-QQ57 ，S6850;NE 52-QQ57, 10 mM in DMSO;GPR4 antagonist 3(NE 52-QQ57 );inhibit,NE 52 QQ57,NE 52-QQ-57,NE 52-QQ57,NE 52QQ57,Inhibitor;2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole;Pyrazolo[1,5-a]pyrimidine, 2-ethyl-5,7-dimethyl-3-[[4-[5-(4-piperidinyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-
- CBNumber:
- CB74658413
- Molecular Formula:
- C24H28N6O
- Molecular Weight:
- 416.52
- MDL Number:
- MFCD31813600
- MOL File:
- 1401728-56-0.mol
- MSDS File:
- SDS
- TDS File:
- TDS
Last updated:2026-06-03 11:24:09
| Product description | Number | Pack Size | Price |
| NE52-QQ57 ≥98% | 40647 | 5mg | $138 |
| NE52-QQ57 ≥98% | 40647 | 10mg | $262 |
| NE52-QQ57 ≥98% | 40647 | 50mg | $757 |
| NE52-QQ57 ≥98% | 40647 | 100mg | $1238 |
| NE 52-QQ57 | BGC72856 | 1mg | $250 |
2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole Properties
| Density | 1.32±0.1 g/cm3(Predicted) |
|---|---|
| storage temp. | Store at -20°C |
| solubility |
DMSO:10.0(Max Conc. mg/mL);24.1(Max Conc. mM) Ethanol:45.0(Max Conc. mg/mL);108.0(Max Conc. mM) |
| form | Solid |
| pka | 9.56±0.10(Predicted) |
| color | White to yellow |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 40647 | NE52-QQ57 ≥98% | 1401728-56-0 | 5mg | $138 | 2026-04-30 | Buy |
| Cayman Chemical | 40647 | NE52-QQ57 ≥98% | 1401728-56-0 | 10mg | $262 | 2026-04-30 | Buy |
| Cayman Chemical | 40647 | NE52-QQ57 ≥98% | 1401728-56-0 | 50mg | $757 | 2026-04-30 | Buy |
| Cayman Chemical | 40647 | NE52-QQ57 ≥98% | 1401728-56-0 | 100mg | $1238 | 2026-04-30 | Buy |
| Biosynth | BGC72856 | NE 52-QQ57 | 1401728-56-0 | 1mg | $250 | 2026-06-04 | Buy |
2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole Chemical Properties,Uses,Production
Uses
NE 52-QQ57 is a selective, and orally available GPR4 antagonist with an IC50 of 70 nM. NE 52-QQ57 has anti-inflammatory activity[1].
in vivo
NE 52-QQ57 (Compound 13) shows a significant anti-inflammatory effect in the rat antigen induced arthritis model after oral administration at 30 mg/kg bid for 20 days[1]. NE 52-QQ57 (30 mg/kg bid po for 4 days) also prevents angiogenesis in the mouse chamber model as well as pain as demonstrated in the rat complete Freund’s adjuvant model[1].
| Animal Model: | Female FVB mice (8-10 weeks)[1] |
| Dosage: | 30 mg/kg |
| Administration: | Oral, 4 days, bid |
| Result: | Treatment at 30 mg/kg p.o. bid starting on day 0, the day of the chamber implantation, showed a statistically significant reduction (46.8±10.6%) of tissue growth by day 4. The blood levels of 13 on day 4 at 2 and 16 h after compound application in this model were 9.03±2.87 and 0.09±0.06 μM[1]. |
| Animal Model: | Male Wistar Han rats[1] |
| Dosage: | 3, 10, and 30 mg/kg |
| Administration: | Oral, 20 days, bid |
| Result: | Displayed not only higher exposures in the rat AIA but also lower plasma protein binding in rat (95%)[1]. |
References
[1] Velcicky J, et al. Development of Selective, Orally Active GPR4 Antagonists with Modulatory Effects on Nociception, Inflammation, and Angiogenesis. J Med Chem. 2017 May 11;60(9):3672-3683. DOI:10.1021/acs.jmedchem.6b01703
[2] Hosford PS, et al. CNS distribution, signalling properties and central effects of G-protein coupled receptor 4. Neuropharmacology. 2018 Aug;138:381-392. DOI:10.1016/j.neuropharm.2018.06.007
Synthesis of 2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole from 3-OXO-PENTANENITRILE
2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole Preparation Products And Raw materials
Raw materials
ter-butyl 4-(2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)benzoyl)hydrazinecarbonyl)piperidine-1-carboxylate
(Z)-4-(2-cyano-3-oxopent-1-en-1-yl)benzonitrile
4-(2-CYANO-3-OXOPENTYL)BENZONITRILE
4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)benzoic acid
4-[(5-amino-3-ethyl-1H-pyrazol-4-yl)methyl]benzonitrile
1of2
Preparation Products
2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole Suppliers
Global( 43)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 33024 | 60 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 | marketing@targetmol.com | United States | 32467 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6391 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; | support@targetmol.com | United States | 39040 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 57505 | 58 | |
| Nanjing Chemlin Chemical Co., Ltd | 025-83697070 13770331960 | info@chemlin.com.cn | China | 16101 | 64 |
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| ShangHai Caerulum Pharma Discovery Co., Ltd. | 18149758185 18149758185 | sales-cpd@caerulumpharma.com | China | 3504 | 58 |
| Shanghai Lollane Biological Technology Co.,Ltd. | 021-52996696，15000506266 15000506266 | China | 4849 | 55 | |
| Shanghai PharmaPartner Co., Ltd. | 19983777532 | pharmabridge@163.com | China | 500 | 55 |
View Lastest Price from 2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-06-02 | NE 52-QQ57
1401728-56-0
|
$42.00-163.00 | 99.93% | 10g | TargetMol Chemicals Inc. | ||
 |
2026-06-02 | NE 52-QQ57
1401728-56-0
|
$42.00-163.00 | 99.93% | 10g | TargetMol Chemicals Inc. |
-
- NE 52-QQ57
1401728-56-0
- $42.00-163.00
- 99.93%
- TargetMol Chemicals Inc.
-
- NE 52-QQ57
1401728-56-0
- $42.00-163.00
- 99.93%
- TargetMol Chemicals Inc.
2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole Spectrum
2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole
GPR4 antagonist 3
Pyrazolo[1,5-a]pyrimidine, 2-ethyl-5,7-dimethyl-3-[[4-[5-(4-piperidinyl)-1,3,4-oxadiazol-2-yl]phenyl]methyl]-
GPR4 antagonist 3(NE 52-QQ57 )
inhibit,NE 52 QQ57,NE 52-QQ-57,NE 52-QQ57,NE 52QQ57,Inhibitor
NE 52-QQ57, 10 mM in DMSO
NE 52-QQ57 ，S6850
1401728-56-0
